|
|
Active Grants
Agency: The Arthritis Society
(TAS)
Title: The Role of Fatty Acid Composition
in Disease Activity and Cardiovascular Disease in Systemic Lupus Erythematosus
Principal Applicant: Paul Fortin,
Ellie Aghdassi
Term: October 2010 - March 2013
Agency: Canadian Institutes
of Health Research (CIHR)
Title: The e-LHP: Dissemination
of the Lupus Health Passport
Principal Applicant: Paul Fortin
Term: April 2010 - March 2011
Agency: Canadian Institutes of Health Research (IMHA)
Title: Lupus Nephritis – New Emerging
Team. (LuNNET)
Principal Applicant: Paul Fortin,
Joan Wither, John Wilkins, Andrew Herzenberg, James Scholey, Joyce Rauch, Christian
Pineau, Ann Clarke, Lawrence Joseph
Term: July 2005 – June 2010
Agency: Mary Kirkland Lupus Foundation
Title: Lupus Clinical Trials Consortium
(LCTC)
Principal Applicants: Paul R. Fortin
on behalf of CaNIOS,
Term: 2004-present
Agency: Canadian Institutes of Health
Research
Title: Learning to live better with
lupus: The health improvement and prevention program (HIPP) in systemic lupus erythematosus
Principal Applicants: Paul R. Fortin,
Deborah DaCosta, Michal Abrahamovicz, Ann E. Clarke, Susan E. Abbey, Robert M. Iwanochko,
Paula J. Harvey, Samuel C. Siu
Term: 2007-2011
Grants Held
Agency: Lupus Foundation
of America
Title: Improving Transition Readiness
and QoL with a Pediatric Health Passport
Principal Applicants: Dr. Emily
Von Scheven with the support of CaNIOS
Term: October 2009 - September 2010
Agency: Canadian Institutes of Health
Research
Title: The role of thrombophilic
factors in persons with systemic lupus erythematosus
Principal Applicants: Paul Fortin,
Jeannine Kassis, Joyce Rauch
Term: 2003-2008
Agency: Canadian Institutes of Health
Research
Title: Genetic and environment factors
in systemic lupus erythematosus (GenES Study)
Principal Applicants: Paul Fortin,
Tom Hdson, Celia Greenwood, Joan Wither, Glinda Cooper
Term: 2003-2008
Agency: Institute of Musculoskeletal
Health and Arthritis / The Arthritis Society
Title: The 1000 Canadian Faces of
Lupus
Principal Applicants: Christine
Peschken, Earl D. Silverman, Janet Pope, Glinda S. Cooper
Term: 2004-2007
Agency: Canadian Institutes
of Health Research
Title: An international, multi-centre,
prospective, inception cohort of neuropsychiatric systemic lupus erythematosus (NP-SLE)
Principal Applicants: John Hanly
Murray Urowitz, Dafna Gladman, Paul Fortin, Ann Clarke, Vern Farewell
Term: 2002-2007
Agency: Institute of Musculoskeletal
Health and Arthritis / The Arthritis Society
Title: Learning to live better with
lupus: The health improvement and prevention program (HIPP) in systemic lupus erythematosus
Principal Applicants: Paul R. Fortin,
Deborah DaCosta, Michal Abrahamovicz, Ann E. Clarke, Susan E. Abbey, Robert M. Iwanochko,
Paula J. Harvey, Samuel C. Siu
Term: 2003-2006
Agency: Canadian Institutes of Health
Research
Title: Malignancy in SLE: A proposal
for a case-control study nested inside the cohort study
Principal Applicants: Ann E. Clarke
Term: 2003-2006
Agency: Canadian Institutes of Health
Research
Title: The prevalence of risk factors
for coronary artery disease in systemic lupus erythematosus: An international multi-centre
prospective cohort study
Principal Applicants: Murray Urowitz,
Ann E. Clarke, Dafna Gladman, Paul Fortin, John Hanly, Lori Tucker
Term: 2001-2006
Agency: National Cancer Institute
of Canada
Title: Does systemic lupus erythematosus
increase the risk of malignancy? An international multi-site retrospective cohort
study
Principal Applicants: Ann Clarke,
Lawrence Joseph, Jean-François Boivin, Raghu Rajan
Term: 2002-2005
Agency: Arthritis Foundation Clinical
Science Grant
Title: An international study on
the relative risk of malignancy in SLE
Principal applicants: Ann Clarke
and Rosalind Ramsey-Goldman
Term: 2001-2004
Agency: Canadian Institutes of Health
Research
Title: The Second Canadian Network
for Improved Outcomes in SLE (CaNIOS) Principal Investigators Annual Meeting
Principal Applicants: Paul Fortin
on behalf of CaNIOS
Term: 2003
Agency: La Jolla Pharmaceuticals
Title: Randomized, double-blind,
placebo-controlled, multicenter safety and efficacy trial of LJP 394 in systemic
lupus erythematosus (SLE) patients with a history of renal disease.
Term: 2000-2002
Agency: The Arthritis Society
Title: The risk of malignancy in
patients with systemic lupus erythematosus
Principal Investigator: Ann Clarke
Term: 1999-2002
Agency: The Arthritis Society with
co-sponsorship by Faulding Canada, Inc.
Title: A Canadian multicenter, randomized,double-blind
placebo-controlled study of methotrexate and folic acid in systemic lupus erythematosus:
A phase III trial. SMILE: Study of methrotrexate in lupus erythematosus
Principal Applicant: Paul Fortin
Term: 1995-2001 (renewal)
Agency: NHRDP
Title: Decreasing costs and improving
outcomes in chronic diseases: Randomized multi-site trial of group psychotherapy
for patients with systemic lupus erythematosus. (LEAP Study)
Principal Applicants: Patricia Dobkin
and Ann Clarke
Term: 1996-2000
Agency: The Arthritis Society with
co-sponsorship by Faulding Canada, Inc.
Title: A Canadian multicenter, randomized,double-blind
placebo-controlled study of methotrexate and folic acid in systemic lupus erythematosus:
A phase III trial. SMILE: Study of methrotrexate in lupus erythematosus
Principal Applicant: Paul Fortin
Term: 1995-1998
|